Inhaled Nitric Oxide Delivery System Market – By Age Group, By Application, By Product, By End Use – Global Forecast, 2025 – 2034

Inhaled Nitric Oxide Delivery System Market Size

The global inhaled nitric oxide delivery system market size was valued at USD 358.7 million in 2024. The market is expected to grow to USD 615.6 million in 2034, at a CAGR of 5.6%. Rising prevalence of respiratory diseases such as acute respiratory distress syndrome and hypoxic respiratory failure, technological advancements in inhaled nitric oxide delivery systems, and increased awareness among healthcare professionals and patients are driving the revenue growth in the market.
 

Acute respiratory distress syndrome is an injury to the lungs which occurs when there is excess fluid in the small air pockets (alveoli) in the lungs. The COVID-19 Pandemic has led to an increase in ARDS cases, which, though with less heterogeneity than multietiologic ARDS populations, still demonstrate marked differences in physiology and outcomes. As per the Cleveland Clinic, approximately 3 million people are diagnosed with ARDS each year around the globe. It contributes to nearly 10% of all admissions to ICUs and is the main cause of about 25% of all cases requiring mechanical ventilation in the hospital. Owing to increasing prevalence of ARDS, the demand for inhaled nitric oxide delivery system is increasing across healthcare settings globally.

 

An inhaled nitric oxide delivery system is a medical device utilized in the administration of therapeutic gases such as nitric oxide to patients suffering from hypoxic respiratory failure (HRF), pulmonary hypertension, and acute respiratory distress syndrome (ARDS) among other conditions. The system accurately administers low-dose nitric oxide (generally within the range of 1-80 ppm) to the lungs that help in expanding pulmonary blood vessels while improving oxygenation without inducing systemic hypotension.
 

Inhaled Nitric Oxide Delivery System Market Trends

• Growing demand for portable and light weight inhaled nitric oxide delivery system targeted for use across ambulatory centers and clinics has led to the increasing number of vendors to introduce their compact systems across new regional markets globally. For instance, in January 2025, Beyond Air announced the global expansion of compact LungFit PH system through several new distribution agreements that will cover four countries such as France, Turkey Romania, and Morocco.
   
• Moreover, vendors now utilize AI through the implementation of real-time monitoring of nitric oxide concentration, oxygen content, and nitrogen dioxide poisoning. This has improved the accuracy of dose controlling and enhanced overall patient safety.
   
• Further, to enhance the portability and safety across hospital settings and overcome  concerns related to logistics and transports, vendors are replacing high-pressure gas cylinders with on-demand nitric oxide generation systems. The advanced nitric oxide generation systems are using electric plasma-based nitric oxide generation to eliminate the need for bulky gas tanks.
   
• Furthermore, the demand for expanding indication of inhaled nitric oxide therapy has led to an increase in investments in research for non-conventional applications such as COPD, COVID-19, and heart failure. For instance, as per the June 2022 study published by Springer Open Journal, the researchers are expanding the role of inhaled nitric oxide in cardio-cerebrovascular and respiratory diseases.
   

Inhaled Nitric Oxide Delivery System Market Analysis

Based on age group, the market is bifurcated into neonatal, pediatric, and adult. The neonatal segment was valued at USD 221.2 million in 2024 and is expected to grow to USD 384.2 million by 2034.
 

• High incidence of newborn respiratory distress among neonatal patients is driving the demand for inhaled nitric oxide therapy in the neonatal segment. According to the 2019 study published by Journal of Health Economics and Outcomes Research, Hypoxic respiratory failure in neonates occurs in 2% of all live births, accounting for more than one-third of neonatal deaths.
   
• Additionally, according to the World Health Organization May 2023 statistics, about 13.4 million babies were born preterm in 2020. The high incidence of preterm birth necessitates the utilization of advanced neonatal ICU (NICU) treatments including inhaled nitric oxide therapy, contributing to the rising demand for inhaled nitric oxide systems, specifically across NICU settings in hospitals.
   
• Further, improved access to neonatal care across developing countries is also contributing to rapid growth in the segment. For instance, as per the Global Health: Science and Practice Journal, at district hospitals, special newborn care units (SNCUs) cater to 0.9 million neonates on FBNC, which is spread over 16 thousand beds throughout India. This contributes to increasing demand for inhaled nitric oxide systems across developing countries, further driving the segment’s growth.
   

Based on application, the inhaled nitric oxide delivery system market is segmented into hypoxic respiratory failure, acute hypoxemic respiratory failure, and other applications. The hypoxic respiratory failure segment shared about 55.3% of the market in 2024 and is expected to grow at a CAGR of 4.7% through 2034.
 

• Inhaled nitric oxide therapy is extensively used in treating hypoxic respiratory failure. According to the Blue Cross and Blue Shield Association, inhaled nitric oxide therapy reduces the need for extracorporeal membrane oxygenation. Since extracorporeal membrane oxygenation is expensive and requires a specially trained team of medical professionals, the use of inhaled nitric oxide therapy is preferred by medical professionals.
   
• Furthermore, inhaled nitric oxide therapy is used as a first-line therapy across tertiary hospitals and pediatric ICUs for treating severe neonatal and pediatric hypoxic respiratory failure, which further drives the revenue growth in the segment.
   

Based on product, the inhaled nitric oxide delivery system market is segmented into disposables and system. The disposables segment generated a revenue of USD 255.7 million in 2024 and is expected to growth at a CAGR of 5.4% during the forecast period.
 

• Presence of strict infection control protocols drives the revenue growth in the disposables segment. As inhaled nitric oxide therapy involves the use of ventilators, disposables such as breathing circuit components, cartridges, cannulas, and catheters are extensively used. Due to strict infection control protocols across healthcare settings to prevent hospital-acquired infections (HAIs), these devices are frequently replaced, which contributes to the revenue growth in the segment.
   
• Additionally, the use of disposables removes the expensive requirement of frequent sterilization, therefore lowering the burden on the hospital while also allowing for quicker patient turnover. Further, vendors offer prepackaged disposable kits which allow for easier setup for inhaled nitric oxide therapy, making these ideal for emergency and ICU settings. This contributes to revenue growth in disposables segment.
   
• In addition, disposables are frequently procured via bulk contracts with GPO’s. Emergency settings and NICU settings across hospitals consistently reorder the disposable which gives the manufacturers steady flow of income and ensuring consistent revenue growth in the segment.
   

Based on end user, the inhaled nitric oxide delivery system market is segmented into hospitals, ambulatory centers, and clinics. The hospitals segment shared about 79.8% of the market in 2024 and is expected to grow at a CAGR of 5.3% through 2034.
 

• Inhaled nitric oxide therapy is most often applied in cases of hypoxic respiratory failure and acute hypoxemic respiratory failure which are life-threatening conditions needing intensive treatment in an ICU. Neonates and pediatric patients suffering from persistent pulmonary hypertension of the newborn are managed in a NICUs, which are typically located in hospitals.
   
• Additionally, a large number of critically ill neonates and adults that need prolonged mechanical breaths and oxygen are treated across hospitals. Inhaled nitric oxide therapy are integrated into the ventilators, which makes the hospitals one of the biggest users of inhaled nitric oxide delivery systems and disposables.
   
• Moreover, inhaled nitric oxide therapy requires specialized ventilators, gas delivery systems, and continuous monitoring, which are all easily available at the hospitals. Typical outpatient settings have limited access to these high-end ventilation and gas management systems, which drives the preference for hospitals, driving the revenue growth in the segment.
   

North America: The U.S. inhaled nitric oxide delivery system market was valued at USD 127.6 million in 2024 and is projected to grow substantially in the coming years.
 

• High prevalence of acute respiratory distress syndrome in the U.S. specifically among neonatal patients is driving the demand for inhaled nitric oxide therapy. According to the Cleaveland Clinic, acute respiratory distress syndrome affects approximately 200,000 patients in the U.S. every year.
   
• Further, according to the Centers for Disease Control and Prevention (CDC), in 2022, preterm births accounted for about 14% of infant deaths. Babies that survived were subjected to breathing problems. As a result, the use of inhaled nitric oxide therapy among preterm newborn was significant in the U.S., driving the demand for inhaled nitric oxide systems.
   
• Additionally, U.S. hosts large number of NICU settings (1,424 NICU settings as per the May 2023 ResearchGate study), ensuring high demand for inhaled nitric oxide systems across its hospitals.
   

Europe: UK inhaled nitric oxide delivery system market is projected to grow remarkably in the coming years.
 

• Increasing incidence of respiratory conditions such as Pneumonia, COVID-19, and chronic lung diseases has contributed to surge in cases of acute respiratory distress syndrome in UK. For instance, according to the King's College Hospital NHS Foundation Trust, each year, between 5-11 adults among every 1,000 get pneumonia in the UK. This has contributed to increasing demand for inhaled nitric oxide therapy.
   
• National Health Service (NHS) in UK covers inhaled nitric oxide therapy as part of neonatal and adult respiratory treatments. This ensures widespread adoption of these therapies in hospitals. Lower out-of-pocket costs for patients encourage broader access to inhaled nitric oxide therapy, driving revenue growth in the country.
   
• Furthermore, presence of key players such as Linde, Mallinckrodt, and Getinge in the UK ensures availability of advanced inhaled nitric oxide delivery systems and consumables, contributing to the market growth in the country.
   

Japan holds a commendable position in the Asia Pacific inhaled nitric oxide delivery system market.
 

• Presence of strong NICU networks supports the steady demand for nitric oxide delivery system in Japan. Through ensuring the use of advanced medical systems NICU across Japan ensures highest-level care in the world. According to the World Bank Group, neonatal care in Japan is advancing day by day, with lowest neonatal mortality rate of 1 per 1,000 live births globally (2022).
   
• Additionally, increasing geriatric population in Japan is also one of the key contributing factor for high incidence of ARDS. According to the World Bank Group, as of 2023, population aged 65 year and above are about 30% of total population in Japan. Elderlies are prone to hypoxic respiratory conditions, which drives the demand for inhaled nitric oxide therapy.
   

Saudi Arabia in the Middle East and Africa is expected to witness lucrative growth in the inhaled nitric oxide delivery system market.
 

• Saudi Arabia has one of the highest birth rates in the region. As per the World Bank Group, birth rate in the country stood at about 2.39 birth per women in 2022. This has contributed to a higher number of neonatal respiratory distress cases. Persistent pulmonary hypertension and hypoxemic respiratory failure are among the leading causes of NICU admissions, making inhaled nitric oxide therapy a critical treatment across hospitals in Saudi Arabia.
   
• In addition, the Saudi Ministry of Health (MOH) focuses on pediatric and neonatal care by ensuring that tertiary hospitals have the presence of advanced medical devices such as inhaled nitric oxide delivery systems. Also, MOH is supporting the improvement of antenatal care by reducing barriers to healthcare access through the implementation of several policies. These include transportation, flexible booking systems, and other amenities for primary health care centers. Such initiatives are driving the use of inhaled nitric oxide therapy in the country.
   
• Furthermore, respiratory illness is one of the key reasons patients are hospitalized for treatment in Saudi Arabia, which has increased the use of inhaled nitric oxide therapies across ICUs. The growing prevalence of obesity hypoventilation syndrome and ARDS (Saudi Arabia has a high obesity rate of 20.2% according to Ministry of Health 2024 statistics) is driving demand for inhaled nitric oxide delivery systems in the country.
   

Inhaled Nitric Oxide Delivery System Market Share

The market for inhaled nitric oxide delivery system is concentrated with top 5 players including Mallinckrodt Pharmaceuticals, Getinge, Linde, Beyond Air, and VERO Biotech sharing about 80% market share. These companies are strongly focusing towards adhering to regulatory compliances to ensure patient safety and improve care. Furthermore, growing focus towards expanding applications of inhaled nitric oxide delivery systems, and improving the compatibility of these systems with ventilators is also leading these players to consistently invest in product research and development. Additionally, the established players are also focusing towards engaging in partnerships to expand their market presence and enhancing product offerings.
 

For example, in January 2023, VERO Biotech received USD 30 million in funding to further develop a tankless system intended to facilitate the delivery of nitric oxide therapy - GENOSYL Delivery System. New entrants in the market face stiff competition from the established players and are focusing on lower pricing strategies to gain competitive edge.
 

Inhaled Nitric Oxide Delivery System Market Companies

Prominent players operating in the inhaled nitric oxide delivery system industry include:

• Air Liquide Healthcare
• Baxter International
• Bellerophon Therapeutics
• Beyond Air
• Circassia Pharmaceuticals
• EKU Elektronik
• Getinge
• International Biomedical
• Linde
• Mallinckrodt Pharmaceuticals
• Merck KGaA
• NU-MED Plus
• Praxair
• SLE
• VERO Biotech
   

• Mallinckrodt Pharmaceuticals offers gold standard product in the market through adhering to regulatory requirements. Its INOmax system is backed by strong clinical data and regulatory approvals. The company also offers integrated respiratory care solutions that are tailored for use across NICUs and PICUs.
• Getinge offers ventilator-integrated inhaled nitric oxide delivery system with ICU expertise that reduces the need of healthcare settings to purchase a separate system. The company also leverages its strong foothold in critical care settings such as operating rooms and ICUs.
   
• Linde, being one of the key suppliers of medical gases, has strong distribution and logistic network. The company offers customizable inhaled nitric oxide delivery system for use across ICU settings and emergency care settings in hospitals. Linde also focuses on offering competitive pricing and cost effective delivery models to expand their market presence.
   

Inhaled Nitric Oxide Delivery System Industry News:

• In October 2024, Beyond Air announced to collaborate with Healthcare Links for expanding the access to their LungFit PH system through group purchasing organizations and integrated delivery networks across the U.S. The partnership aims to streamline the integration of LungFit PH into healthcare facilities in order to improve the patient outcomes.
   
• In December 2023, Mallinckrodt Pharmaceuticals received FDA clearance for their INOmax EVOLVE DS delivery system which intakes and delivers nitrous oxide gas for inhalation with improved synchrony and compatibility with different ventilators.
   
• In December 2023, VERO Biotech announced its strategic partnership with US Med-Equip to boost hospitals' on-demand access to the GENOSYL Delivery System. US Med-Equip’s experience with medical equipment logistics promotes the proper distribution and instillation of the GENOSYL system across healthcare facilities, increasing access to inhaled nitric oxide therapy for patients in critical care.
   
• In January 2023, VERO Biotech received FDA approval for their GENOSYL Delivery System, a third generation, tankless and portable system for inhaled nitric oxide delivery. This system is designed to provide consistent inhaled nitric oxide gas dosage with virtually no logistical challenges owing to its large tanks. Additionally, the system is portable and has ergonomic interface to help improve its efficiency in the clinic.
   

The inhaled nitric oxide delivery system market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Age Group

• Neonatal
• Pediatric
• Adult

Market, By Application

• Hypoxic respiratory failure
• Acute hypoxemic respiratory failure
• Other applications

Market, By Product

• Disposables
• System

Market, By End Use

• Hospitals
• Ambulatory centers
• Clinics

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE